PMEF
MCRB icon

Point72 Middle East FZE’s Seres Therapeutics MCRB Stock Holding History

Point72 Middle East FZE’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,950
Closed -$54.6K – 810
2023
Q4 		$54.6K Buy
+1,950
New +$51.2K ﹤0.01% 1275
2023
Q1 		– Sell
-541
Closed -$60.5K – 1974
2022
Q4 		$60.5K Buy
+541
New +$72.5K ﹤0.01% 1405

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Point72 Middle East FZE's MCRB Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Seres Therapeutics (MCRB) in Q1 2024, closing a stake of 1,950 shares — an estimated $54.6K sold.

Point72 Middle East FZE first reported a position in MCRB in Q4 2022 and held it in 2 quarters. The position peaked at $60.5K in Q4 2022. 99 funds tracked by Wall St. Rank hold MCRB as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Seres Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 1,950 Seres Therapeutics shares in Q1 2024, an estimated $54.6K.
  • Point72 Middle East FZE first reported a position in Seres Therapeutics in Q4 2022 and held it in 2 quarters.
  • Point72 Middle East FZE's Seres Therapeutics position peaked at $60.5K in Q4 2022.
  • 99 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.